Atomic Resolution Structure of Monomorphic Aβ<sub>42</sub> Amyloid Fibrils

Michael T. Colvin(Massachusetts Institute of Technology), Robert Silvers(Massachusetts Institute of Technology), Qing Zhe Ni(Massachusetts Institute of Technology), Thach V. Can(Massachusetts Institute of Technology), Ivan V. Sergeyev(Bruker (United States)), Mélanie Rosay(Bruker (United States)), K. J. Donovan(Massachusetts Institute of Technology), Brian Michael(Massachusetts Institute of Technology), Joseph S. Wall(Brookhaven National Laboratory), Sara Linse(Lund University), Robert G. Griffin(Massachusetts Institute of Technology)
Journal of the American Chemical Society
June 29, 2016
Cited by 811Open Access
Full Text

Abstract

Amyloid-β (Aβ) is a 39-42 residue protein produced by the cleavage of the amyloid precursor protein (APP), which subsequently aggregates to form cross-β amyloid fibrils that are a hallmark of Alzheimer's disease (AD). The most prominent forms of Aβ are Aβ1-40 and Aβ1-42, which differ by two amino acids (I and A) at the C-terminus. However, Aβ42 is more neurotoxic and essential to the etiology of AD. Here, we present an atomic resolution structure of a monomorphic form of AβM01-42 amyloid fibrils derived from over 500 (13)C-(13)C, (13)C-(15)N distance and backbone angle structural constraints obtained from high field magic angle spinning NMR spectra. The structure (PDB ID: 5KK3 ) shows that the fibril core consists of a dimer of Aβ42 molecules, each containing four β-strands in a S-shaped amyloid fold, and arranged in a manner that generates two hydrophobic cores that are capped at the end of the chain by a salt bridge. The outer surface of the monomers presents hydrophilic side chains to the solvent. The interface between the monomers of the dimer shows clear contacts between M35 of one molecule and L17 and Q15 of the second. Intermolecular (13)C-(15)N constraints demonstrate that the amyloid fibrils are parallel in register. The RMSD of the backbone structure (Q15-A42) is 0.71 ± 0.12 Å and of all heavy atoms is 1.07 ± 0.08 Å. The structure provides a point of departure for the design of drugs that bind to the fibril surface and therefore interfere with secondary nucleation and for other therapeutic approaches to mitigate Aβ42 aggregation.


Related Papers

No related papers found

Powered by citation graph analysis